IL310354A - Water soluble prodrug, conjugates and uses thereof - Google Patents
Water soluble prodrug, conjugates and uses thereofInfo
- Publication number
- IL310354A IL310354A IL310354A IL31035424A IL310354A IL 310354 A IL310354 A IL 310354A IL 310354 A IL310354 A IL 310354A IL 31035424 A IL31035424 A IL 31035424A IL 310354 A IL310354 A IL 310354A
- Authority
- IL
- Israel
- Prior art keywords
- moiety
- conjugate
- compound
- oligo
- auristatin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL28520821 | 2021-07-28 | ||
| PCT/IL2022/050782 WO2023007481A1 (en) | 2021-07-28 | 2022-07-20 | Water soluble prodrug, conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL310354A true IL310354A (en) | 2024-03-01 |
Family
ID=85086377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL310354A IL310354A (en) | 2021-07-28 | 2022-07-20 | Water soluble prodrug, conjugates and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4377292A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024532677A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117999254A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022318483A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3226393A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL310354A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023007481A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4566631A1 (en) * | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017531620A (ja) * | 2014-09-12 | 2017-10-26 | ジェネンテック, インコーポレイテッド | システイン操作抗体及びコンジュゲート |
| KR102710962B1 (ko) * | 2017-07-04 | 2024-09-27 | 주식회사 인투셀 | 절단성 링커를 포함하는 화합물 및 이들의 용도 |
| AU2019365238A1 (en) * | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
| CN113613679A (zh) * | 2019-03-19 | 2021-11-05 | 保罗·谢勒学院 | 基于甘氨酸的接头的转谷氨酰胺酶缀合方法 |
-
2022
- 2022-07-20 AU AU2022318483A patent/AU2022318483A1/en active Pending
- 2022-07-20 CN CN202280053086.7A patent/CN117999254A/zh active Pending
- 2022-07-20 IL IL310354A patent/IL310354A/en unknown
- 2022-07-20 WO PCT/IL2022/050782 patent/WO2023007481A1/en not_active Ceased
- 2022-07-20 EP EP22848817.7A patent/EP4377292A4/en active Pending
- 2022-07-20 CA CA3226393A patent/CA3226393A1/en active Pending
- 2022-07-20 JP JP2024505333A patent/JP2024532677A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4377292A4 (en) | 2026-06-03 |
| AU2022318483A1 (en) | 2024-02-22 |
| EP4377292A1 (en) | 2024-06-05 |
| CN117999254A (zh) | 2024-05-07 |
| WO2023007481A1 (en) | 2023-02-02 |
| JP2024532677A (ja) | 2024-09-10 |
| CA3226393A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022204013B2 (en) | Targeted delivery of tertiary amine-containing drug substances | |
| JP7257951B2 (ja) | 改善された生理化学的特性を有する自己安定性リンカーを用いる薬物コンジュゲート | |
| JP7620991B6 (ja) | 標的送達及び活性化した免疫刺激性複合体の調製と使用 | |
| AU2022204711B9 (en) | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation | |
| TWI814699B (zh) | 四級胺化妥布賴森(tubulysin)化合物之結合物 | |
| TWI900494B (zh) | 從生物活性化合物的內化共軛物選擇性釋出藥物 | |
| CN112752759A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途 | |
| CN103379912B (zh) | 正羧烷基耳他汀及其应用 | |
| EP3288593A1 (en) | Conjugate of monomethyl auristatin f and trastuzumab and its use for the treatment of cancer | |
| CN106170303A (zh) | 通过半胱天冬酶激活的前体药物 | |
| JP2018512376A (ja) | 抗体薬物コンジュゲート | |
| IL195236A (en) | Aziridinyl-epothilone compounds, use thereof for preparation of a medicament and a process for making a pharmaceutical composition | |
| TW202506105A (zh) | 連接子-藥物分子及抗體藥物偶聯物、其製備方法和應用 | |
| WO2023007481A1 (en) | Water soluble prodrug, conjugates and uses thereof | |
| WO2025077572A1 (zh) | 一种用于前药给药系统的可裂解连接体化合物及其制备和应用 | |
| WO2025031923A1 (en) | Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications | |
| HK40111022A (en) | Water soluble prodrug, conjugates and uses thereof | |
| US9669106B2 (en) | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | |
| KR20240016231A (ko) | 신규 오리스타틴 전구약물 | |
| HK40065994A (en) | Targeted delivery of tertiary amine-containing drug substances | |
| HK40079820B (en) | Targeted delivery of tertiary amine-containing drug substances | |
| HK40104908A (en) | Antibody-drug conjugate including antibody against human cldn18.2, and use thereof | |
| TW202613076A (zh) | 鏈接子-有效負載、由其作成之抗體-藥物共軛物及其用途 | |
| CN121449623A (zh) | 一种拓扑异构酶抑制剂及其偶联物的应用 | |
| WO2026107097A1 (en) | Self-immolative linkers and conjugates thereof |